Chronic Spontaneous Urticaria Plasma
Chronic Spontaneous Urticaria Plasma — human plasma from IRB-consented donors with clinically confirmed CSU, processed within one day of collection. Suited to mast cell mediator profiling, total and specific IgE work, and coagulation-pathway analytes such as D-dimer that are best preserved in plasma. Donors can be stratified by UAS7, antihistamine responsiveness, and omalizumab treatment status.
Chronic Spontaneous Urticaria Plasma for Mast Cell and Type 2 Inflammation Research
Chronic Spontaneous Urticaria Plasma is collected from IRB-consented donors clinically diagnosed with chronic spontaneous urticaria (CSU) and processed within one day of collection to preserve cytokines, proteins, and metabolites. CSU is a mast cell-driven condition in which cutaneous mast cells degranulate without an identifiable external trigger, producing recurrent wheals, angioedema, or both for more than six weeks. Plasma from these donors supports research into mast cell activation, IgE biology, and the coagulation-adjacent changes described in this disease.
Why Plasma for Chronic Spontaneous Urticaria Research
- The proximate event in CSU is skin mast cell degranulation with release of histamine, tryptase, platelet-activating factor and downstream vasoactive mediators. Circulating mediator and mediator-metabolite levels are the accessible readout of that process.
- CSU is an IgE-centred disease at the receptor level: signalling through FcepsilonRI on mast cells and basophils is what omalizumab, an anti-IgE antibody, interrupts. Total IgE is an established plasma analyte with recognised relevance to treatment response research.
- Two endotypes are described in the literature — a type I autoallergic form with IgE directed at autoantigens, and a type IIb autoimmune form with functional IgG autoantibodies against IgE or FcepsilonRI. Soluble samples are the substrate for endotype-assignment assay development.
- Activation of the extrinsic coagulation cascade, with raised D-dimer and thrombin generation tracking disease activity, is one of the better-replicated systemic findings in CSU. These analytes require anticoagulated plasma and are not reliably measurable in serum.
- Basopenia and altered basophil responsiveness are recognised features of active CSU; plasma from the same draw contextualises paired basophil and PBMC work.
- Because CSU is defined by fluctuating activity, plasma is well suited to longitudinal and pre/post-treatment sampling in which the same donor supplies an internal comparator.
Donor Stratification Available
- Disease activity by UAS7 or comparable urticaria activity instrument
- Presence of angioedema in addition to wheals, versus wheals alone
- Antihistamine responsiveness: controlled on standard dose, controlled on up-dosed second-generation antihistamine, or antihistamine-refractory
- Treatment status: omalizumab-treated, omalizumab-naive, on ciclosporin or other systemic immunomodulator, or in washout
- Total IgE level and thyroid autoantibody status where available
- Disease duration and comorbid autoimmune thyroid disease
- Matched healthy controls available
Product Features
- Research Use Only (RUO)
- Plasma collected from clinically confirmed chronic spontaneous urticaria donors
- Processed within one day of collection
- Anticoagulant selection available on request, including citrate for coagulation-pathway work
- IRB-approved protocols and informed consent
- Custom aliquot volumes available upon request
De-identified Donor Data
- Verified chronic spontaneous urticaria diagnosis
- Demographic data: age, sex assigned at birth, race/ethnicity
- Donor-reported medications, allergies, and comorbidities
- Disease activity scoring and treatment history where available
- Additional chronic spontaneous urticaria-specific metadata available on request
Applications
- Mast cell mediator and tryptase profiling in an active disease matrix
- Total IgE quantification and anti-IgE therapeutic research
- Coagulation activation studies, including D-dimer and thrombin generation, in relation to disease activity
- Endotype-assignment assay development for autoallergic versus autoimmune CSU
- Type 2 cytokine and chemokine multiplex profiling
- Biomarker discovery for disease activity, remission and treatment response
- Proteomic comparison of CSU against other type 2 and mast cell-driven conditions
- Assay development and validation using disease-state plasma as a clinically relevant matrix
Other Chronic Spontaneous Urticaria Specimen Types
- Chronic Spontaneous Urticaria Serum
- Chronic Spontaneous Urticaria Whole Blood
- Chronic Spontaneous Urticaria PBMC
- Chronic Spontaneous Urticaria Skin Punch Biopsy
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Chronic spontaneous urticaria plasma is available in standard and custom volumes. For pricing, availability, or to discuss a stratified cohort, email learnmore@sanguinebio.com. For international orders or documentation requirements, please contact us to ensure compatibility with your country’s regulations. To browse plasma across all disease states and healthy donors, visit our human plasma page.
Protocols & Documentation
-
Download
Plasma Isolation
Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Plasma
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.